TNDM Stock Forecast & Price Target

Tandem Diabetes Care is supported by a business model shift that is improving economics, as PayGo is gaining traction with 10% of U.S. sales through the pharmacy channel, 45% formulary coverage, and supply ASPs above the $350/month assumption, even if $0 upfront shipments created about an $8MM Q2 headwind. Demand also appears healthy beneath the accounting noise, with record Q2 shipments of 22K pumps, new starts up 20%+ sequentially, and MDI conversions representing about 70% of new pump starts, while Mobi already accounts for more than half of new customer shipments. Longer term, the company has multiple growth drivers in a large under-penetrated market, including Mobi Tubeless under FDA review for a 2H'26 launch, a potentially meaningful 2027 contribution, and a pipeline that includes the Sigi patch pump and Control-IQ enhancements.

Tandem Diabetes Care is viewed negatively because its growth thesis is exposed to slower-than-expected U.S. and international Mobi adoption, tougher competition, and the possibility that new products and R&D efforts fail to meaningfully expand patient starts or protect renewals. The company is also vulnerable to reimbursement pressure, supply-chain disruptions such as infusion-set shortages, and GLP-1-related demand risk, all of which could limit durable revenue growth in a business that is highly concentrated in insulin delivery systems and derives nearly three-quarters of sales from the US. Although it reported $247M of revenue with 55.3% gross margin and 1.1% adjusted EBITDA margin, the outlook remains cautious because it may never achieve consistent profitability and may struggle to meet long-term targets.